Ultra-long-acting cabotegravir could be taken three times a year for HIV PrEP and treatment
Switch to an integrase inhibitor leads to greater weight during and after the menopause
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
Once-weekly antiretrovirals on the horizon
If one antibody won’t work, how about three? Or three in one?
Varying dolutegravir distribution across the body may affect the drug’s ability to suppress the HIV reservoir
Injectable treatment just as effective as standard HIV combination in Africa
Greater weight gain in pregnancy reduces the risk of adverse outcomes for women with HIV
